GlassScriptPhysician profile
Young K Kim
NPI 1932106911
$3,642.32
in general payments reported to CMS, 2019-2025
30 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $285 · 2021: $613 · 2022: $610 · 2023: $827 · 2024: $613 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $966.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $576.39 | 2019-2025 | |
| Lilly USA, LLC | $336.93 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $271.47 | 2022-2024 | Amplatzer Talisman, Freestyle Libre 3 |
| Abbvie INC. | $192.07 | 2021-2023 | |
| Amarin Pharma, INC. | $180.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $162.63 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Xeris Pharmaceuticals, INC. | $101.31 | 2022-2025 | Gvoke Hypopen |
| Amgen INC. | $93.36 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $89.78 | 2021-2022 | |
| Exact Sciences Corporation | $87.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $56.41 | 2022-2025 | Zoryve, Seglentis |
| Otsuka America Pharmaceutical, INC. | $56.12 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $51.84 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Vanda Pharmaceuticals INC. | $51.51 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $46.60 | 2019 | |
| Mylan Specialty L.P. | $37.29 | 2020-2021 | |
| Seqirus USA INC | $31.28 | 2024-2025 | Fluad, Flucelvax |
| Allergan, INC. | $29.95 | 2020 | |
| Astellas Pharma US INC | $28.64 | 2024 | Veozah |
| Daiichi Sankyo INC. | $28.57 | 2025 | Injectafer |
| Ucb, INC. | $24.13 | 2020 | |
| Becton, Dickinson and Company | $22.53 | 2025 | Bd Max System, Bd Max Instrument |
| Sunovion Pharmaceuticals INC. | $21.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.71 | 2022 | |
| Dexcom, INC. | $17.63 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.22 | 2024 | Voquezna |
| Linus Health, INC. | $15.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.